Surmodics INC

Surmodics, Inc. has completed its merger with BCE Parent, LLC, becoming a private entity with shareholders receiving $43.00 per share in cash.

A U.S. District Court denied the FTC's request for a preliminary injunction, moving Surmodics' proposed acquisition by GTCR closer to completion.

Surmodics reports mixed third-quarter fiscal 2025 financial results, with growth in Pounce Thrombectomy and IVD segments offset by declines in SurVeil DCB revenue, while updating full-year guidance amidst ongoing FTC merger litigation.

Surmodics, Inc. announced a cyber incident involving unauthorized access to its IT systems, but reports critical systems are restored and customer operations remain uninterrupted.

Surmodics announced its Q2 fiscal year 2025 financial results, revealing a revenue decrease and GAAP loss, while also introducing financial guidance for the remainder of the fiscal year, all while navigating a pending acquisition by GTCR and related FTC litigation.

The FTC has filed a complaint to block the proposed acquisition of Surmodics by GTCR due to concerns about its potential impact on competition.

Surmodics reports a narrower quarterly net loss but faces revenue declines and ongoing FTC litigation challenging its proposed acquisition.

Surmodics' Q2 2025 results reveal a revenue decrease and operating loss, overshadowed by ongoing legal challenges from the FTC regarding its acquisition by BCE Parent, LLC.

Surmodics' first quarter of fiscal year 2025 saw a net loss of $3.651 million, impacted by merger-related charges and a decrease in SurVeil DCB product sales.

Surmodics' Q3 2024 results show a significant revenue decrease due to a prior year milestone payment, alongside increased product sales and a pending merger agreement.

Surmodics saw a significant increase in revenue in the second quarter of 2024, primarily driven by growth in its Medical Device segment, particularly from the commercial launch of its SurVeil drug-coated balloon.

Surmodics' first quarter of fiscal year 2024 saw a 23% increase in revenue, primarily driven by strong performance in the Medical Device segment.

Surmodics' fiscal year 2024 saw a revenue decrease and a net loss, with the company anticipating further revenue declines in 2025 due to reduced SurVeil DCB sales, all while navigating a pending merger.

Surmodics SVP Charles W. Olson reported the conversion of his common stock and stock options into cash following the company's merger into a wholly-owned subsidiary of BCE Parent, LLC.

Surmodics Inc. VP Finance, Corp. Controller John D. Manders reported the conversion of his common stock, RSUs, and stock options into cash following the company's acquisition by BCE Parent, LLC.

Gordon S. Weber, Surmodics' Sr. VP of Legal, GC and Sec., disposed of all common stock and options following the company's merger into BCE Parent, LLC.

Surmodics Inc.'s SVP, Teri Woodwick Sides, reported the disposition of all common stock and conversion of equity awards to cash following the company's merger into BCE Parent, LLC at $43.00 per share.

Surmodics Director David Dantzker disposed of all common stock and stock options following the company's merger into a wholly-owned subsidiary.

A director of Surmodics Inc. reported the disposition of all common stock and derivative securities following the company's merger into a wholly-owned subsidiary of BCE Parent, LLC.

Surmodics, Inc. has filed a definitive proxy statement with the SEC in preparation for its upcoming shareholder meeting.

Surmodics, Inc. has scheduled its annual shareholder meeting for February 6, 2025, as a virtual event, while also navigating a pending merger agreement.

Surmodics and BCE Parent, LLC receive a second request for information from the FTC, extending the waiting period for their merger, but still anticipate closing the deal by February 28, 2025.

Surmodics, Inc. has entered into a definitive agreement to be acquired by an entity indirectly controlled by GTCR LLC for $43.00 per share in cash.

Surmodics has entered into a definitive agreement to be acquired by GTCR, a private equity firm, for $43.00 per share in cash, valuing the company at approximately $627 million.

Surmodics, Inc. has entered into a definitive agreement to be acquired by GTCR for $43.00 per share in cash, representing an approximate equity value of $627 million.

GAMCO Investors and affiliated entities have divested their entire beneficial ownership in Surmodics Inc. following the completion of its acquisition by an affiliate of GTCR LLC.

A group of investment entities led by Mario Gabelli has disclosed a 5.02% beneficial ownership stake in Surmodics Inc., acquired for investment purposes with a focus on enhancing shareholder value.

Trium Capital LLP has fully divested its entire stake in Surmodics Inc, reducing its beneficial ownership to zero percent.

Soleus Capital and its affiliates have reported a complete divestment of their beneficial ownership in Surmodics, Inc., reducing their stake to 0% as of September 30, 2025.

Trium Capital LLP has disclosed a 5.0% beneficial ownership stake in Surmodics Inc., holding 716,783 shares of common stock for investment purposes.

AllianceBernstein L.P. has disclosed a 5.9% beneficial ownership stake in Surmodics Inc., holding 849,354 common shares for investment purposes.

Barclays PLC has filed an amended Schedule 13G, indicating its beneficial ownership of Surmodics Inc. common stock remains at 5% or less, held in the ordinary course of business.

Barclays PLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 7.26% of Surmodics Inc's common stock, totaling 1,039,058 shares as of December 31, 2024.